FGGY Inhibitors

FGGY inhibitors are compounds that target the FGGY carbohydrate kinase domain-containing proteins. Due to the absence of direct inhibitors, focus has been directed towards chemicals that can exert an indirect influence on the functional dynamics of FGGY kinases by modulating the metabolic pathways they are associated with.

Compounds such as Metformin and AICAR, which are activators of AMPK, play critical roles in cellular energy homeostasis. Their activation can modulate various metabolic pathways, creating an environment where FGGY kinases might have altered activity. Conversely, Compound C and Dorsomorphin, both AMPK inhibitors, showcase the intricate balance required in metabolic regulation, wherein the inhibition of a central regulator can reverberate effects on proteins such as the FGGY kinases. Furthermore, chemicals such as 2-Deoxy-D-glucose and WZB117, which affect glucose metabolism, shed light on the importance of glycolytic and gluconeogenic pathways in the broader function of FGGY kinases. Berberine and Resveratrol, both of which have been associated with metabolic modulations, can also cast their effects on pathways involving FGGY kinases. The inclusion of PPAR activators and agonists like Fenofibrate and Rosiglitazone represents the importance of lipid metabolism in this scenario.